Company Profile · Healthcare

Inhibrx Inc

INBX_OLD · US

Country: USA
IPO date: Aug 19, 2020
Employees: 156
Website: inhibrx.com

Buffett Score

22/100

Poor

Financial snapshot

Market cap$220.18M

Revenue (TTM)$200K

EBITDA-$229.86M

Profit margin861,485.5%

ROE41.18%

P/E (TTM)0.12

Forward P/E0

EPS$124.00

52-week range$0.00 – $0.00

Analyst target$12.00

Analyst rating3.0 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock

No reports on this stock in your language yet.